Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Pharmacyclics Inc (PCYC)    
$89.75 0.29 (0.32%) as of 4:30 Thu 4/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 67,916,000 as of 6/30
Market Cap: 6.10(B)
Last Volume: 1,397,148 Avg Vol: 815,282
52 Week Range: $74.479 - $151.61
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY       NASDAQ COMPOSITE  
    NASDAQ NNM COMPOSITE  

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   Pharmacyclics is a biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Co. has three proprietary drug candidates under clinical development and several preclinical lead molecules: an inhibitor of Bruton's tyrosine kinase (BTK) ibrutinib in several Phase III studies in hematologic malignancies, a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications, an inhibitor of Factor VIIa in a Phase II clinical trial in pancreatic cancer and a histone deacetylase inhibitor, abexinostat, in Phase I and II clinical trials in solid tumors and hematological malignancies.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 144,370 243,370 339,836 666,971
Total Sell Value $20,657,003 $31,142,530 $39,850,110 $59,155,598
Total People Sold 7 10 12 15
Total Sell Transactions 10 16 21 40
End Date 2014-01-19 2013-10-18 2013-04-19 2012-04-19

   
Records found: 334
  Page 1 of 14  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Outten Matthew VP, Commercial OperationsOffic   •       –      –    2014-03-10 3 IO $0.00 $0 I/I 0 180 -32%     
   Outten Matthew VP, Commercial OperationsOffic   •       –      –    2014-03-10 3 IO $0.00 $0 D/D 0 10,554 -32%     
   Hemmi Gregory Sr. VP Chemical Operations   •       –      –    2014-03-05 4 OE $0.86 $12,900 D/D 15,000 53,004     -
   Sjovall Boultbee Paula S EVP, Sales and Marketing   •       –      –    2014-03-05 4 OE $25.94 $162,203 D/D 6,253 7,992     -
   Sjovall Boultbee Paula S EVP, Sales and Marketing   •       –      –    2014-03-05 4 S $140.75 $880,115 D/D (6,253) 1,739 36%     
   Mcgreivy Jesse Chief Medical Officer   •       –      –    2014-03-05 4 OE $25.33 $166,241 D/D 6,563 6,563     -
   Mcgreivy Jesse Chief Medical Officer   •       –      –    2014-03-05 4 S $139.66 $916,599 D/D (6,563) 0 36%     
   Hemmi Gregory Sr. VP Chemical Operations   •       –      –    2014-03-05 4 S $140.00 $2,100,033 D/D (15,000) 38,004 36%     
   Fardis Maria Chief of Oncology Ops & Allian   •       –      –    2014-03-05 4 OE $6.84 $20,520 D/D 3,000 5,988     -
   Fardis Maria Chief of Oncology Ops & Allian   •       –      –    2014-03-05 4 S $140.50 $421,504 D/D (3,000) 2,988 36%     
   Sjovall Boultbee Paula S EVP, Sales and Marketing   •       –      –    2014-03-04 4 OE $25.94 $356,597 D/D 13,747 15,486     -
   Chang Betty Y VP, Research/Biology   •       –      –    2014-03-04 4 OE $7.69 $179,238 D/D 17,500 21,254     -
   Chang Betty Y VP, Research/Biology   •       –      –    2014-03-04 4 S $137.97 $2,414,484 D/D (17,500) 3,754 34%     
   Halvorson Eric H Director   –       •      –    2014-03-04 4 OE $14.26 $61,332 D/D 3,472 4,472     -
   Halvorson Eric H Director   –       •      –    2014-03-04 4 S $138.33 $480,282 D/D (3,472) 1,000 34%     
   Sjovall Boultbee Paula S EVP, Sales and Marketing   •       –      –    2014-03-04 4 S $137.07 $1,884,330 D/D (13,747) 1,739 34%     
   Van Den Broek Richard Director   –       •      –    2014-02-27 4 S $144.92 $3,622,990 I/I (25,000) 29,610 38%     
   Van Den Broek Richard Director   –       •      –    2014-02-26 4 S $147.13 $3,778,170 I/I (25,680) 54,610 39%     
   Van Den Broek Richard Director   –       •      –    2014-02-25 4 S $147.70 $4,158,496 I/I (28,155) 80,290 39%     
   Soni Manmeet Singh Chief Financial Officer   •       –      –    2014-02-04 4 A $0.00 $0 D/D 32,000 32,406     -
   Duggan Robert W Chairman and CEO   •       •       •   2013-12-30 5 GA $0.00 $0 I/I 3,290 30,312     -
   Duggan Robert W Chairman and CEO   •       •       •   2013-12-30 5 GD $0.00 $0 D/D 3,290 13,492,378     -
   Hemmi Gregory VP Chemical Operations   •       –      –    2013-12-30 4 OE $0.75 $9,750 D/D 13,000 38,004     -
   Tan Heow Chief Quality&Tech Operations   •       –      –    2013-12-24 4 OE $27.05 $40,575 D/D 1,500 1,669     -
   Duggan Robert W Chairman and CEO   •       •       •   2013-12-24 5 GA $0.00 $0 I/I 21,438 21,438     -

  334 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 14
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed